Allergic conjunctivitis (AC) is the most common form of allergic eye disease and an increasingly prevalent condition. Topical eye drop treatments are the usual approach for managing AC, although their impact on the ocular surface is not frequently investigated. The aim of this study was to perform a comparative physicochemical characterization, and in vitro biological evaluations in primary conjunctival and corneal epithelial cells of the new multidose preservative-free bilastine 0.6% and main commercially available eye drops. Bilastine and single-dose ketotifen and azelastine showed high survival rates attributable to the absence of preservative in its formulation, not inducing caspase-3/7-mediated apoptosis after 24 h. Our findings support the use of the new bilastine 0.6% for treating patients with AC to preserve and maintain the integrity of the ocular surface.
Scientific Reports. 2024 Apr 26
Metabolic syndrome is characterized by dysregulated glucose metabolism and is
We are pleased to announce that Innoprot has been recognised
Acetyl-l-carnitine (ALC) is synthesized in the brain, liver, and kidneys
Neural stem cell (NSC) proliferation and differentiation in the mammalian
Allergic conjunctivitis (AC) is the most common form of allergic
The hepatic content of amyloid beta (Aβ) decreases drastically in